|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||3.34 - 3.54|
|52 Week Range||2.95 - 5.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.92|
Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.
Achillion Pharmaceuticals saw its shares make a handy gain on Thursday after the company announced a secondary offering.
NEW YORK, NY / ACCESSWIRE / November 16, 2017 / U.S. markets dropped sharply Wednesday, with the Dow and S&P 500 posting its largest daily loss since September, as sliding oil prices dragged down the energy ...
NEW HAVEN, Conn., Nov. 15, 2017-- Achillion Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson ...
It was just two months ago when shares of Achillion Pharmaceuticals (ACHN) were crushed by news that its all-important hepatitis C partnership with Johnson & Johnson (JNJ) had come to an end. Today, the drug maker’s share price is in free fall once again, dropping more than 10% in recent market action after Achillion announced that J&J’s venture capital arm, Johnson & Johnson Innovations-JJDC intends to sell its entire stake in Achillion (all 18,367,346 shares) in a secondary offering, and that Achillion will not receive any proceeds. Separately, Achillion released mid-stage data for the experimental drug ACH-4471, a treatment for a rare disease known as C3 glomerulopathy in which protein deposits build up in the patient’s kidneys.
Regulatory actions and licensing and collaboration agreements were the key highlights this week with companies like Loxo Oncology (LOXO) remaining in the limelight.
Cardinal Health (CAH) will streamline its Chinese operations by disposing pharmaceutical and medical products distribution business in China.
Theravance (TBPH) submits the NDA for its key candidate, revefenacin, to the FDA for treating adults with chronic obstructive pulmonary disease.
Achillion Pharmaceuticals Inc. shares fell in the extended session Tuesday after the drug developer reported promising early data on one of its kidney-disease treatments but said a large stakeholder was ...
NEW HAVEN, Conn., Nov. 14, 2017-- Achillion Pharmaceuticals, Inc. today announced that Johnson & Johnson Innovation-JJDC, Inc., an existing stockholder of Achillion, intends to offer for sale in an underwritten ...
-Greater than 50% improvement in proteinuria after 14 days of oral dosing with ACH-4471-. -Improvement in complement alternative pathway biomarkers observed-. NEW HAVEN, Conn., Nov. 14, 2017-- Achillion ...
GlaxoSmithKline's (GSK) Benlysta receives approval for a new subcutaneous formulation in Europe as an add-on therapy for patients with SLE.
NEW HAVEN, Conn., Nov. 06, 2017-- Achillion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted orphan drug designation to ACH-4471 for the treatment of paroxysmal ...
Achillion Pharmaceuticals' (ACHN) third-quarter loss was narrower than estimates. The company is focusing on expanding its key pipeline candidate in several indications.
The New Haven, Connecticut-based company said it had a loss of 14 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
NEW HAVEN, Conn., Nov. 01, 2017-- Achillion Pharmaceuticals, Inc. today reported financial results for the three months ended September 30, 2017. For the third quarter of 2017, Achillion reported a net ...
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Achillion Pharmaceuticals Inc (NASDAQ:ACHN), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...
NEW HAVEN, Conn., Oct. 23, 2017-- Achillion Pharmaceuticals, Inc. reported today Phase 2 b data on JNJ-4178, the triple combination consisting of odalasvir, AL-335, simeprevir, following presentations ...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Achillion Pharmaceuticals, Inc. a score of 17. Our analysis is based on comparing Achillion Pharmaceuticals, Inc. with the following peers – Vertex Pharmaceuticals Incorporated, Gilead Sciences, Inc., Bristol-Myers Squibb Company, Enanta Pharmaceuticals, Inc., GlaxoSmithKline plc Sponsored ADR, Johnson & Johnson, NanoViricides, Inc., AbbVie, Inc., Merck & Co., ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Achillion Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
NEW HAVEN, Conn., Sept. 20, 2017-- Achillion Pharmaceuticals, Inc. announced today that members of the senior management team will provide a corporate update at the 2017 Leerink Partners Rare Disease Roundtable ...